NCT00234117

Brief Summary

The purpose of this study is to determine if 20mg BID of Rabeprazole is effective in controlling GERD in patients with concomitant bronchial asthma and to assess improvement in asthma after reflux control.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2005

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 5, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 6, 2005

Completed
Last Updated

July 22, 2011

Status Verified

October 1, 2005

First QC Date

October 5, 2005

Last Update Submit

July 20, 2011

Conditions

Bronchial AsthmaGastroesophageal Reflux

Outcome Measures

Primary Outcomes (1)

  • Efficacy of rabeprazole treatment will be described using the proportion of the subjects with complete acid suppression at week 12

Interventions

RabeprazoleDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Moderate Persistent or moderate severe bronchial asthma as determined by the study pulmonologist
  • Gastroesophageal Reflux disease

You may not qualify if:

  • History of hypersensitivity to rabeprazole or its metabolites

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ponce Gastroentrology Research

Ponce, 00717, Puerto Rico

Location

MeSH Terms

Conditions

AsthmaGastroesophageal Reflux

Interventions

Rabeprazole

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEsophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Alvaro Reymunde, MD

    Ponce Gastroenterology Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 5, 2005

First Posted

October 6, 2005

Study Start

July 1, 2005

Last Updated

July 22, 2011

Record last verified: 2005-10

Locations

PR(1)